Niagen Bioscience Expands NAD+ IP Portfolio with Newly Issued U.S. Patent for Intravenous and Injectable Nicotinamide Riboside (NR) Formulations
Niagen Bioscience, Inc, a recognized global authority on NAD+ (nicotinamide adenine dinucleotide) and a leader in the science of healthy aging, today announced a significant expansion of its intellectual property (IP) portfolio. The company has been granted U.S. Patent No. 12,558,367, covering novel methods of use for nicotinamide riboside (NR) and its derivatives in intravenous (IV) and injectable formulations. This development strengthens Niagen Bioscience’s position at the forefront of the burgeoning NAD+ and healthy aging markets while reinforcing its exclusive rights to advanced delivery formats for its flagship product, Niagen®.
Rob Fried, CEO of Niagen Bioscience, emphasized the strategic importance of this new patent, stating, “This patent expands our intellectual property for our patented NR ingredient, Niagen®, into IV and injectable delivery formats. With expected protection through 2044, it supports Niagen’s exclusivity in delivering a superior IV and injectable product with significantly faster delivery and improved comfort for patients across our expanding U.S. clinic footprint.”
The newly issued patent reflects Niagen Bioscience’s ongoing commitment to innovation in NAD+ science and its application in health and longevity. The patent specifically protects methods for formulating NR in aqueous intravenous solutions as well as injectable formulations. These formats are particularly important because they allow for rapid and efficient elevation of NAD+ levels within the body, providing potential therapeutic and wellness benefits that cannot be achieved as quickly with oral administration alone.
Under its Niagen Plus product portfolio, Niagen Bioscience has developed a next-generation intravenous formulation of pharmaceutical-grade NR. This product is designed to enhance cellular health and promote healthy aging and longevity at the cellular level. Compared to traditional NAD+ IV treatments, the aqueous-based intravenous Niagen formulation offers several advantages. It allows for faster infusion times, elevates NAD+ levels more effectively, and reduces the risk of severe side effects commonly associated with standard NAD+ IV administration. According to recent studies, including those by Reyna et al. (2026) and Hawkins et al. (2024), these improvements in safety and efficacy enhance the commercial relevance of Niagen’s IV and injectable products.
Niagen Bioscience has long been recognized for its leadership in NAD+ precursor development. The company owns and licenses an extensive portfolio of intellectual property covering more than 100 patents worldwide. This portfolio not only includes Niagen but also encompasses a variety of other NAD+ precursors and formulations. By continuously exploring next-generation compounds and delivery methods, the company maintains a competitive edge in the fast-growing healthy aging and longevity market.
The newly granted U.S. Patent No. 12,558,367 further strengthens Niagen Bioscience’s defensible IP footprint by specifically addressing intravenous and injectable delivery methods for NR. The patent includes claims that cover aqueous formulations, multiple administration routes, defined administration parameters, select NR salt forms, and combination use with other NAD+ precursors. These claims provide broad protection that supports commercial expansion and potential partnerships, while also safeguarding the company’s innovation from competitors.
From a commercial perspective, the patent has significant implications. It enables Niagen Bioscience to pursue multiple delivery platforms for its NR products, offering flexibility to clinicians and patients seeking advanced NAD+ therapies. The patent also reinforces the company’s ability to collaborate with other organizations in the health and wellness, clinical, and pharmaceutical spaces. By securing exclusive rights to these next-generation IV and injectable formulations, Niagen Bioscience is well-positioned to leverage its technology in both direct-to-consumer wellness clinics and broader clinical applications.
Moreover, the issuance of this patent aligns with the company’s broader strategy of building a durable and defensible IP portfolio. By continuously innovating in the areas of formulation, delivery, and combination therapies, Niagen Bioscience is able to maintain a leading position in the healthy aging industry. The patent provides long-term protection for the company’s IV and injectable NR products, potentially extending well into the mid-21st century, thereby ensuring that Niagen retains its competitive advantage in a rapidly expanding market.
In addition to its patent activities, Niagen Bioscience has been actively evaluating next-generation NAD+ precursors and delivery methods to support its commitment to cellular health and longevity. The company’s research and development efforts focus on identifying molecules and formulations that can maximize NAD+ availability, improve tolerability, and enhance patient experience. This dedication to innovation, coupled with a strong IP portfolio, positions Niagen Bioscience as a global leader in NAD+ technology and its applications in healthy aging.
The company’s leadership in this area has been consistently recognized, and the issuance of U.S. Patent No. 12,558,367 underscores its ongoing role in advancing the science of NAD+ and healthy aging. As the market for NAD+ therapies continues to grow, particularly in the context of wellness, longevity, and clinical applications, the value of Niagen Bioscience’s intellectual property and next-generation formulations is expected to increase significantly.
In conclusion, Niagen Bioscience’s newly granted patent represents a major milestone in the company’s efforts to expand its IP portfolio, strengthen commercial opportunities, and maintain its leadership in the NAD+ and healthy aging space. By covering intravenous and injectable formulations of NR, the patent ensures that Niagen Bioscience can continue to provide innovative, safe, and effective solutions for elevating NAD+ levels. This development not only protects the company’s proprietary technology but also reinforces its commitment to advancing the science of healthy aging, supporting patients and consumers alike in achieving optimal cellular health and longevity.
